β-Lactam-based approach for the chemical programming of aldolase antibody 38C2

Article abstract of DOI:10.1016/j.bmcl.2009.01.028

Irreversible chemical programming of monoclonal aldolase antibody (mAb) 38C2 has been accomplished with β-lactam-equipped targeting modules. A model study was first performed with β-lactam conjugated to biotin. This conjugate efficiently and selectively modified the catalytic site lysine (LysH93) of mAb 38C2. We then conjugated a β-lactam to a cyclic-RGD peptide to chemically program mAb 38C2 to target integrin receptors α_vβ₃ and α_vβ₅. The chemically programmed antibody bound specifically to the isolated integrin receptor proteins as well as the integrins expressed on human melanoma cells. This approach provides an efficient and versatile solution to irreversible chemical programming of aldolase antibodies.

Full text of DOI:10.1016/j.bmcl.2009.01.028

Bioorganic & Medicinal Chemistry Letters 19 (2009) 1421–1424
Contents lists available at ScienceDirect
Bioorganic & Medicinal Chemistry Letters
journal homepage: www.elsevier.com/locate/bmcl
b-Lactam-based approach for the chemical programming of aldolase
antibody 38C2
*
Julia I. Gavrilyuk, Ulrich Wuellner, Carlos F. Barbas III
The Skaggs Institute for Chemical Biology and the Departments of Molecular Biology and Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road,
La Jolla, CA 92037, USA
a r t i c l e i n f o
a b s t r a c t
Article history:
Irreversible chemical programming of monoclonal aldolase antibody (mAb) 38C2 has been accomplished
with b-lactam-equipped targeting modules. A model study was first performed with b-lactam conjugated
to biotin. This conjugate efficiently and selectively modified the catalytic site lysine (LysH93) of mAb
38C2. We then conjugated a b-lactam to a cyclic-RGD peptide to chemically program mAb 38C2 to target
Received 10 December 2008
Revised 7 January 2009
Accepted 12 January 2009
Available online 15 January 2009
integrin receptors avb3 and avb5. The chemically programmed antibody bound specifically to the isolated
integrin receptor proteins as well as the integrins expressed on human melanoma cells. This approach
provides an efficient and versatile solution to irreversible chemical programming of aldolase antibodies.
Ó 2009 Elsevier Ltd. All rights reserved.
Keywords:
Monoclonal antibody
Aldolase antibody
Chemically programmed antibody
Integrins
Monoclonal antibody (mAb) 38C2 was generated by reactive
immunization with a 1,3-diketone hapten.1 This antibody pos-
sesses a lysine residue at position 93 of the heavy chain, LysH93,
that has an unusually low pKa of ꢀ6.0 and is essential for the cat-
alytic mechanism of the antibody.2 mAb 38C2 can be chemically
programmed to selectively bind to cells or other targets by selec-
tive reaction of LysH93 with b-diketone (Scheme 1A) or an acetone
aldol adduct of a vinylketone (Scheme 1B) linker equipped with a
targeting ligand or module.3–8 Many of our studies have used
thiazolium-dependent catalytic antibodies.9 Given the success of
this study and the chemical stability of the resulting covalent mod-
ification, we were encouraged to examine this approach as a route
to chemically programmed antibodies. Here we report the selec-
tive reaction of the catalytic site LysH93 with b-lactam-equipped
targeting modules (Scheme 1C); the synthesis of the targeting
module was straightforward and this strategy provides for irre-
versible covalent attachment of targeting modules. We designed
antagonists of
avb3 and avb5 integrins as targeting modules for
chemical programming of aldolase antibody specificity.3–7 In the
first case, a reversible covalent attachment of a diketone com-
pound is achieved through the formation of an imine, which iso-
merizes to the more stable enaminone derivative. In the latter
case, an acetone aldol adduct of the vinylketone is used as a prolin-
ker, because the vinylketone linker is highly reactive. mAb 38C2
catalyzes the retro-aldol reaction of the prolinker to give free
vinylketone linker, which then undergoes Michael addition, in situ,
with the catalytic Lys residue in the antibody-binding site. This ap-
proach provides irreversible attachment of the targeting modules;
however, preparation of the prolinker equipped targeting modules
requires complicated multistep synthesis and is not compatible
with a wide range of substrates.
In earlier studies we had explored a b-lactam-based modifica-
tion strategy for covalent attachment of thiazolium cofactor into
the active site of aldolase antibodies in order to prepare the first
* Corresponding author. Tel.: +1 858 784 9098; fax: +1 858 784 2583.
E-mail address: carlos@scripps.edu (C.F. Barbas).
Scheme 1. Different approaches for the chemical programming of mAb 38C2 using
a reactive moiety linked to a targeting module (TM).
0960-894X/$ - see front matter Ó 2009 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmcl.2009.01.028

1422
J. I. Gavrilyuk et al. / Bioorg. Med. Chem. Lett. 19 (2009) 1421–1424
activity of mAb 38C2 was observed after 2 h at room temperature.
Catalytic activity was measured by analysis of the retro-aldol reac-
tion of methodol (Fig. 1A).3 Aliquots were removed at different
timepoints and the reaction was quenched by immediate removal
of any unbound small molecules by desalting using Zeba spin
desalting columns (Pierce Inc.); the resulting purified antibody
was tested in the methodol-based catalytic activity assay. MAL-
DI-TOF analysis of the biotin programmed mAb 38C2 compared
Scheme 2. Synthesis of the heterobifunctional linker module 3.
our linker molecules with three features in mind: First, 1-acyl b-
lactams react efficiently with LysH93.9 Second, the narrow and
highly lipophilic catalytic site of mAb 38C2 should bind tightly to
a phenyl ring based on the crystal structure of the antibody.2 Third,
given the disposition of LysH93 at the bottom of the 11-Å deep ac-
tive site, a linker of appropriate length should be incorporated to
allow functional display of the targeting module outside the active
site of the antibody.
The heterobifunctional b-lactam targeting module 3 was syn-
thesized in six steps starting from inexpensive starting materials.
In brief, 2-(2-(2-chloroethoxy)ethoxy)ethanol 1 was treated with
sodium azide in DMF to afford the corresponding azido alcohol in
89% yield (Scheme 2). Subsequent tosylation provided tosyl azide
2 in quantitative yield. Reaction of 2 with ethyl 4-hydroxybenzoate
in the presence of potassium carbonate in DMF provided azido es-
ter in 76% isolated yield. The ester was hydrolyzed using lithium
hydroxide followed by a reaction with neat thionyl chloride to give
the corresponding acid chloride. The crude acid chloride was used
immediately for the reaction with 2-azetidinone in the presence of
n-butyl lithium to afford the desired heterobifunctional module 3
in 44% isolated yield.
We selected biotin as a model targeting module to evaluate the
b-lactam-based approach for chemical programming of mAb 38C2.
Biotin containing 6 was prepared as follows: biotin N-hydroxy-
succinimide ester 4 was coupled with propargyl amine to give
alkynyl biotin 5 in 96% yield (Scheme 3).
The subsequent copper (I)-catalyzed azide alkyne cycloaddition
reaction10–15 of b-lactam module 3 and alkyne 5 furnished the de-
sired targeting module 6 in 87% isolated yield.
Chemical programming of the mAb 38C2 with 6 was performed
essentially as described.3 Only 2 equiv of the targeting module 6
were used (1 equiv per active site) and complete loss of catalytic
Figure 1. Analysis of the formation of mAb 38C2 chemically programmed with 6
(cp38C2-6). (A) The methodol-based catalytic activity assay of aliquots removed
and quenched by desalting at indicated timepoints. (B) Overlay of MALDI-TOF
analysis of mAb 38C2 and cp38C2-6. (C) Results of the ELISA assay showing
streptavidin-HRPO binding of mAb 38C2 alone, cp38C2-6, commercially available
biotinylated mouse Ab (positive control), and BSA.
Scheme 3. Synthesis of the b-lactam-biotin conjugate 6.

J. I. Gavrilyuk et al. / Bioorg. Med. Chem. Lett. 19 (2009) 1421–1424
1423
Scheme 4. Synthesis of the azido-functionalized cyclic-RGD module 10.
biotin in a manner to allow for its binding to streptavidin, we also
used a streptavidin ELISA (Fig. 1C). We then chemically pro-
grammed the antibody to recognize integrin receptors
avb3 and
avb5 in order to explore the compatability of the b-lactam linker
strategy with a substantially more functionalized targeting mod-
ule. Heterobifunctional linker 9 containing azide and NHS func-
tionalities was prepared starting from triethyleneglycol
(Scheme 4).
7
Triethylene glycol was bis-tosylated and converted to the corre-
sponding bis-azide in excellent yield. The bis-azide was selectively
reduced using an established procedure to give amino azide 8.16
Reaction of 8 with succinic anhydride and subsequent coupling
with N-hydroxysuccinimide provided the desired heterobifinction-
Scheme 5. Synthesis of the heterobifunctional linker module 12.
al linker 9. Linker 9 was selectively conjugated with the
group of the lysine moiety in the cyclic-RGD peptide (cyclo(Arg-
Gly-Asp- -Phe-Lys)) to give module 10. We also prepared linker
e-amino
D
module 12 (Scheme 5) in order to introduce the b-lactam function-
ality into our integrin targeting module.
Triethylene glycol 7 was treated with propargyl bromide in the
presence of sodium hydride to afford a mixture of mono- and bis-
propargylated products that were separated by column chroma-
tography. Mono-propargylated alcohol was then tosylated to af-
ford tosyl alkyne 11. Compound 11 was reacted with ethyl 4-
hydroxybenzoate in the presence of potassium carbonate in DMF
to afford the alkynyl ester in 98% yield without need for purifica-
tion. The ester was hydrolyzed using lithium hydroxide and con-
verted to the acid chloride by treatment with neat thionyl
chloride. The crude acid chloride was used immediately for the
reaction with 2-azetidinone in the presence of n-butyl lithium to
afford the desired heterobifunctional linker 12 in 51% isolated
yield.
Scheme 6. Synthesis of the b-lactam-equipped cyclic-RGD conjugate 13.
to that of mAb 38C2 gave an additional proof of the selective func-
tionalization of catalytic site LysH93 in the context of the IgG
(Fig. 1B).9 Analysis of tryptic digests confirmed LysH93 labeling.
To confirm that the chemically programmed antibody displayed
Figure 2. cp38C2 binds to integrins
unprogrammed mAb 38C2, antibody specific for the integrin
vb5. Here the integrin vb5-specific antibody P1F6 was used as a positive control (C) Analysis of cp38C2 binding to human melanoma M21 cells. Autofluorescence of M21
a
vb3 and
a
vb5 (Chemicon). (A) ELISA demonstrating preferential binding of cp38C2 (38C2/RGD) to integrin
avb3. Controls were
avb3 (LM609) and BSA as a negative control antigen. (B) ELISA demonstrating preferential binding of cp38C2 to
a
a
cells is represented as purple line; cells were stained with cp38C2 (red line), unprogrammed mAb 38C2 (green line), LM609 antibody (blue line) that acts as a positive control,
and secondary antibody alone (orange line). Bound antibodies were detected with Cy5-conjugated donkey anti-mouse IgG.

1424
J. I. Gavrilyuk et al. / Bioorg. Med. Chem. Lett. 19 (2009) 1421–1424
The integrin targeting module 13 was synthesized in a copper
References and notes
(I)-catalyzed azide alkyne cycloaddition reaction of the heterobi-
functional module 12 with the azido-targeting module 10 (Scheme
6). The resulting b-lactam-equipped targeting module was incu-
bated with mAb 38C2 to provide chemically programmed (cp)
1. Wagner, J.; Lerner, R. A.; Barbas, C. F., 3rd Science 1995, 270, 1797.
2. Barbas, C. F., 3rd; Heine, A.; Zhong, G.; Hoffmann, T.; Gramatikova, S.;
Bjornestedt, R.; List, B.; Anderson, J.; Stura, E. A.; Wilson, I. A.; Lerner, R. A.
Science 1997, 278, 2085.
3. Rader, C.; Sinha, S. C.; Popkov, M.; Lerner, R. A.; Barbas, C. F., III Proc. Natl. Acad.
Sci. U.S.A. 2003, 100, 5396.
antibody. Binding of the cp38C2 to human integrins
a
avb3 and
vb5 was confirmed by ELISA (Fig. 2A and B).3,7 Importantly, the
4. Li, L. S.; Rader, C.; Matsushita, M.; Das, S.; Barbas, C. F., III; Lerner, R. A.; Sinha, S.
C. J. Med. Chem. 2004, 47, 5630.
chemically programmed antibody recognized the integrins on liv-
5. Guo, F.; Das, S.; Mueller, B. M.; Barbas, C. F., III; Lerner, R. A.; Sinha, S. C. Proc.
Natl. Acad. Sci. U.S.A. 2006, 103, 11009.
6. Sinha, S. C.; Das, S.; Li, L. S.; Lerner, R. A.; Barbas, C. F., III Nat. Protoc. 2007, 2, 449.
7. Popkov, M.; Rader, C.; Gonzalez, B.; Sinha, S. C.; Barbas, C. F., III Int. J. Cancer
2006, 119, 1194.
8. Doppalapudi, V. R.; Tryder, N.; Li, L. N.; Aja, T.; Griffith, D.; Liao, F. F.; Roxas, G.;
Ramprasad, M. P.; Bradshaw, C.; Barbas, C. F., III Bioorg. Med. Chem. Lett. 2007,
17, 501.
9. Tanaka, F.; Lerner, R. A.; Barbas, C. F., III Chem. Commun. 1999, 1383; Chemical
programming of 38C2 with b-lactam linkers was initially disclosed in US Patent
Publication No. 2003-175921, with additional discussion in US Publication No.
2006-0205670 (CovX Technologies) and WO Publication No. 2008056346
(CovX Technologies).
ing cells: cp38C2 bound to human melanoma M21 cells that ex-
press both integrins
expected, unprogrammed catalytic antibody 38C2 did not bind to
M21 cells.
In conclusion, we have prepared b-lactam-equipped targeting
modules and demonstrated that these modules can be used to pre-
pare chemically programmed antibodies. The modular strategy and
use of bioorthogonal click chemistry for the preparation of b-lac-
tam-equipped targeting modules allowed straightforward access
to these valuable immunotherapeutics. Further studies of the ther-
avb3 and a
vb5 on their surface (Fig. 2C).7 As
10. Sen Gupta, S.; Kuzelka, J.; Singh, P.; Lewis, W. G.; Manchester, M.; Finn, M. G.
Bioconj. Chem. 2005, 16, 1572.
11. Agard, N. J.; Baskin, J. M.; Prescher, J. A.; Lo, A.; Bertozzi, C. R. ACS Chem. Biol.
2006, 1, 644.
apeutic effect of targeting integrin
avb3 and avb5 receptors with
chemically programmed mAb 38C2 are underway and will be re-
ported in the due course.
12. Devaraj, N. K.; Collman, J. P. QSAR Comb. Sci. 2007, 26, 1253.
13. Li, J.; Duan, M.; Zhang, L. H.; Jiang, X. H. Prog. Chem. 2007, 19, 1754.
14. Hein, C. D.; Liu, X. M.; Wang, D. Pharm. Res. 2008, 25, 2216.
15. Tron, G. C.; Pirali, T.; Billington, R. A.; Canonico, P. L.; Sorba, G.; Genazzani, A. A.
Med Res Rev 2008, 28, 278.
Acknowledgment
This work was supported by Grant RO1 CA104045 from the Na-
tional Institutes of Health.
16. Schwabacher, A. W.; Lane, J. W.; Schiesher, M. W.; Leigh, K. M.; Johnson, C. W. J.
Org. Chem. 1998, 63, 1727.